tiprankstipranks
Trending News
More News >
Collegium Pharmaceutical Inc. (COLL)
:COLL
US Market

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Compare
473 Followers
See the Price Targets and Ratings of:

COLL Analyst Ratings

Strong Buy
5Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Collegium
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

COLL Stock 12 Month Forecast

Average Price Target

$43.25
▲(45.67%Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Collegium Pharmaceutical in the last 3 months. The average price target is $43.25 with a high forecast of $50.00 and a low forecast of $37.00. The average price target represents a 45.67% change from the last price of $29.69.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","51":"$51","32.25":"$32.3","38.5":"$38.5","44.75":"$44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,32.25,38.5,44.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.06,28.824615384615385,30.589230769230767,32.35384615384615,34.11846153846154,35.88307692307692,37.64769230769231,39.41230769230769,41.176923076923075,42.94153846153846,44.706153846153846,46.470769230769235,48.23538461538462,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.06,28.305384615384614,29.55076923076923,30.796153846153846,32.04153846153846,33.286923076923074,34.53230769230769,35.777692307692305,37.02307692307692,38.26846153846154,39.51384615384615,40.75923076923077,42.004615384615384,{"y":43.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.06,27.824615384615385,28.589230769230767,29.353846153846153,30.11846153846154,30.88307692307692,31.647692307692306,32.41230769230769,33.176923076923075,33.941538461538464,34.706153846153846,35.47076923076923,36.23538461538462,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.88,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.78,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.14,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.62,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.59,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.46,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.7,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.46,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.12,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.06,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$43.25Lowest Price Target$37.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on COLL
TipRanks AITipRanks
Not Ranked
TipRanks
$33
Buy
11.15%
Upside
Reiterated
05/30/25
Collegium Pharmaceutical shows strong fundamentals with notable revenue growth and strategic initiatives, although high leverage and decreased profitability present risks. Positive earnings sentiment and sound technical indicators enhance the outlook, while a high valuation limits upside potential.
Truist Financial Analyst forecast on COLL
Les SulewskiTruist Financial
Truist Financial
Buy
Reiterated
05/09/25
Truist Financial Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)
Needham
$46
Buy
54.93%
Upside
Reiterated
05/09/25
Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (NASDAQ: ALXO), Collegium Pharmaceutical (NASDAQ: COLL) and Theravance Biopharma (NASDAQ: TBPH)
Piper Sandler Analyst forecast on COLL
David AmsellemPiper Sandler
Piper Sandler
$36$37
Hold
24.62%
Upside
Reiterated
05/09/25
Collegium Pharmaceutical price target raised to $37 from $36 at Piper SandlerCollegium Pharmaceutical price target raised to $37 from $36 at Piper Sandler
H.C. Wainwright Analyst forecast on COLL
Oren LivnatH.C. Wainwright
H.C. Wainwright
$50
Buy
68.41%
Upside
Reiterated
03/21/25
Collegium Pharmaceutical: Undervalued Stock with Strong Growth Potential and Low Risk
Jefferies
$40
Buy
34.73%
Upside
Reiterated
03/17/25
Glen Santangelo Reiterates Buy Rating on Collegium Pharmaceutical, Citing Undervalued Pain Portfolio and Strong Market Positioning
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on COLL
TipRanks AITipRanks
Not Ranked
TipRanks
$33
Buy
11.15%
Upside
Reiterated
05/30/25
Collegium Pharmaceutical shows strong fundamentals with notable revenue growth and strategic initiatives, although high leverage and decreased profitability present risks. Positive earnings sentiment and sound technical indicators enhance the outlook, while a high valuation limits upside potential.
Truist Financial Analyst forecast on COLL
Les SulewskiTruist Financial
Truist Financial
Buy
Reiterated
05/09/25
Truist Financial Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)
Needham
$46
Buy
54.93%
Upside
Reiterated
05/09/25
Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (NASDAQ: ALXO), Collegium Pharmaceutical (NASDAQ: COLL) and Theravance Biopharma (NASDAQ: TBPH)
Piper Sandler Analyst forecast on COLL
David AmsellemPiper Sandler
Piper Sandler
$36$37
Hold
24.62%
Upside
Reiterated
05/09/25
Collegium Pharmaceutical price target raised to $37 from $36 at Piper SandlerCollegium Pharmaceutical price target raised to $37 from $36 at Piper Sandler
H.C. Wainwright Analyst forecast on COLL
Oren LivnatH.C. Wainwright
H.C. Wainwright
$50
Buy
68.41%
Upside
Reiterated
03/21/25
Collegium Pharmaceutical: Undervalued Stock with Strong Growth Potential and Low Risk
Jefferies
$40
Buy
34.73%
Upside
Reiterated
03/17/25
Glen Santangelo Reiterates Buy Rating on Collegium Pharmaceutical, Citing Undervalued Pain Portfolio and Strong Market Positioning
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Collegium Pharmaceutical

1 Month
xxx
Success Rate
17/31 ratings generated profit
55%
Average Return
+0.50%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.84% of your transactions generating a profit, with an average return of +0.50% per trade.
3 Months
xxx
Success Rate
12/31 ratings generated profit
39%
Average Return
+0.82%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.71% of your transactions generating a profit, with an average return of +0.82% per trade.
1 Year
Success Rate
15/31 ratings generated profit
48%
Average Return
+6.59%
reiterated a buy rating last month
Copying Serge Belanger's trades and holding each position for 1 Year would result in 48.39% of your transactions generating a profit, with an average return of +6.59% per trade.
2 Years
xxx
Success Rate
23/31 ratings generated profit
74%
Average Return
+25.24%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 74.19% of your transactions generating a profit, with an average return of +25.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

COLL Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
2
3
3
3
3
Buy
3
3
3
2
2
Hold
3
3
3
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
9
9
9
8
In the current month, COLL has received 5 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. COLL average Analyst price target in the past 3 months is 43.25.
Each month's total comprises the sum of three months' worth of ratings.

COLL Financial Forecast

COLL Earnings Forecast

Next quarter’s earnings estimate for COLL is $1.65 with a range of $1.62 to $1.72. The previous quarter’s EPS was $1.49. COLL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year COLL has Outperformed its overall industry.
Next quarter’s earnings estimate for COLL is $1.65 with a range of $1.62 to $1.72. The previous quarter’s EPS was $1.49. COLL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year COLL has Outperformed its overall industry.

COLL Sales Forecast

Next quarter’s sales forecast for COLL is $182.69M with a range of $181.98M to $184.19M. The previous quarter’s sales results were $177.76M. COLL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year COLL has Outperformed its overall industry.
Next quarter’s sales forecast for COLL is $182.69M with a range of $181.98M to $184.19M. The previous quarter’s sales results were $177.76M. COLL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year COLL has Outperformed its overall industry.

COLL Stock Forecast FAQ

What is COLL’s average 12-month price target, according to analysts?
Based on analyst ratings, Collegium Pharmaceutical Inc.’s 12-month average price target is 43.25.
    What is COLL’s upside potential, based on the analysts’ average price target?
    Collegium Pharmaceutical Inc. has 45.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is COLL a Buy, Sell or Hold?
          Collegium Pharmaceutical Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Collegium Pharmaceutical Inc.’s price target?
            The average price target for Collegium Pharmaceutical Inc. is 43.25. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $50.00 ,the lowest forecast is $37.00. The average price target represents 45.67% Increase from the current price of $29.69.
              What do analysts say about Collegium Pharmaceutical Inc.?
              Collegium Pharmaceutical Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of COLL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis